Eyenovia announced that in light of recent progress in its Optejet spray dispenser for ophthalmic medications, it plans on applying for US regulatory approval in the fourth quarter of 2025. According to a company press release, rigorous testing shows the device's’s durable base unit performing more than 30,000 sprays, 98% of which were between 8-9 mL (approximately equal to the amount of liquid the eye can hold) over 180 doses, meeting exacting specifications. The submission would mark a key step toward commercialization of the device.

Eyenovia says that Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The new design includes a sterile disposable cartridge that users can fill using their own, fresh eyedropper bottle. The cartridge is then attached to the reusable base unit; once empty, it can be replaced with a new cartridge.

“Millions of consumers have difficulty with traditional eye drops, including difficulty with inaccurate administration, discomfort from head tilting, messing up make-up and waste and potential side effects associated with excess drops, all of which could be addressed with the Optejet,” noted Michael Rowe, chief executive officer of Eyenovia, in the press release.